Outlook Therapeutics (OTLK) Liabilities and Shareholders Equity (2015 - 2026)

Outlook Therapeutics (OTLK) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $21.9 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $21.9 million, up 14.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $81.1 million (down 27.58% YoY), and the FY2025 annual result was $18.6 million, down 35.52% from the prior year.
• Liabilities and Shareholders Equity grew to $21.9 million in Q1 2026 per OTLK's latest filing, from $18.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $67.7 million in Q1 2022 and troughed at $17.0 million in Q4 2024.
• A 5-year average of $35.4 million and a median of $28.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity jumped 50.04% in 2022, then slumped 67.68% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $62.7 million in 2022, then tumbled by 65.41% to $21.7 million in 2023, then fell by 21.58% to $17.0 million in 2024, then gained by 7.25% to $18.2 million in 2025, then rose by 20.03% to $21.9 million in 2026.
• Business Quant data shows OTLK's Liabilities and Shareholders Equity at $21.9 million in Q1 2026, $18.2 million in Q4 2025, and $18.6 million in Q3 2025.